学名药的日本市场评估:各用途，各类型，不同品牌，各给药途径，各流通管道，各地区，机会，预测(2018年度～2032年度)

日本仿製药市场规模预计将从 2024 财年的 127.2 亿美元增至 2032 财年的 232.3 亿美元，在预测期内（2024 财年至 2032 财年）复合年增长率为 7.81%。市场成长受到以下因素的支持：政府减少医疗保健支出的政策、出生率下降导致的人口老化以及製药公司增加联盟和伙伴关係以增加该国仿製药的供应。

包括呼吸系统疾病和紊乱在内的慢性病的盛行率不断上升，也推动了对日本仿製药市场的需求。根据多芬医学出版社2024年5月发表的文章，日本气流阻塞的盛行率为3.8%至16.9%。这增加了对仿製药的需求，因为它们在给药途径、强度、品质和给药方面与品牌药相当，同时为患者提供了经济的替代方案。为了减少国民医疗保健支出，日本政府也实施了各种鼓励仿製药采用的政策。

此外，医疗保健专业人员和患者越来越多地使用产品也可能是由于人们对仿製药带来的好处的认识不断提高，这推动了日本仿製药市场的规模。此外，厚生劳动省也推出了仿製药推广措施，为2022年医疗费用调整做准备。

此外，2023 年 2 月发表在 Biomed Central 上的一项研究认为，随着患者月收入的减少，门诊医院和门诊处方中仿製药的使用量会增加。

癌症、糖尿病和心血管疾病等疾病的盛行率不断上升，推动了对仿製药的需求。这些慢性病往往需要长期用药，而仿製药的使用可以让患者以经济有效的方式管理自己的病情，凸显了仿製药在慢性病管理中的重要角色。

政府支持的成长机会

日本政府正在增加对教育活动的投资，以提高公众意识并促进仿製药的使用。厚生劳动省也鼓励大型药品生产公司与中小型药品生产商合併，促进仿製药生产，确保稳定供应。该部也旨在振兴製药业，加速国内药物开发。药品是卫生系统的主要支出之一，降低药品成本是政府和政策制定者减少开支、扩大医疗覆盖范围、改善药品取得的当务之急，这是一项永恆的挑战。因此，仿製药的采用正在增加，对市场成长产生正面影响。

老年人口扩大带动市场需求

过去几十年来，人口老化增加了对仿製药的关注，以降低医疗保健行业的成本。根据世界经济论坛估计，日本近三分之一的人口年龄在65岁以上，超过十分之一的人口年龄在80岁以上。这种增长增加了该国对仿製药的需求，因为老年人更容易患各种疾病和病症，需要定期用药。仿製药与原厂药含有相同的活性成分，因此在具有与专利药相同的给药方法、功效、剂量和效果的同时，具有经济高效性。因此，日本对仿製药的偏好正在增加。

品牌仿製药占较大市占率

各种慢性病盛行率的增加以及市场进入者推出的产品数量的增加正在支持日本仿製药市场的成长。 2023年4月，持田製药股份有限公司宣布推出曲普罗吸入溶液，用于治疗肺动脉高压。

本报告对日本仿製药市场进行研究和分析，提供市场规模和预测、市场动态以及主要公司的现状和前景。

目录

第1章 计划的范围和定义

第2章 调查手法

第3章 摘要整理

第4章 日本的学名药市场预测(2018年度～2032年度)

• 市场规模的分析与预测
  • 金额
  • 数量
• 市场占有率分析与预测
  • 各用途
  • 各类型
  • 不同品牌
  • 各给药途径
  • 各流通管道
  • 各地区
  • 市场占有率分析:各企业(金额)(前五名公司和其他 - 2024年度)
• 市场地图分析(2024年度)
  • 各用途
  • 各类型
  • 不同品牌
  • 各给药途径
  • 各流通管道
  • 各地区

第5章 供需分析

第6章 进口和出口的分析

第7章 价值链分析

第8章 波特的五力分析

第9章 大环境分析

第10章 价格分析

第11章 市场动态

• 推动市场要素
• 市场课题

第12章 市场趋势与发展

第13章 法规结构和革新

• 生物有效性/生物学的同等性实验
• 法规当局的认证

第14章 专利的有效期限

第15章 案例研究

第16章 竞争情形

• 市场领导者前五名公司的竞争矩阵
• 前五名公司的SWOT分析
• 主要企业前十大企业的形势
  • Takeda Pharmaceutical Co., Ltd.
  • Teva Pharmaceuticals Industries Ltd.
  • Sun Pharma Japan Limited
  • Nichi-Iko Pharmaceutical Co., Ltd.
  • OHARA Pharmaceutical Co., Ltd.
  • DAIICHI SANKYO COMPANY, LIMITED
  • Meiji Seika Pharma
  • Biocon Biologics Limited
  • Mochida Pharmaceutical Co., Ltd.
  • NIHON GENERIC Co., Ltd.

第17章 策略性推荐

第18章 本公司相关资料，免责声明

Japan generic drugs market is projected to witness a CAGR of 7.81% during the forecast period FY2024-FY2032, growing from USD 12.72 billion in FY2024 to USD 23.23 billion in FY2032. The market's growth is supported by government policies to reduce healthcare expenditure, expanding aging population due to low birth rates, and rising collaborations and partnerships by pharmaceutical companies to boost the availability of generic drugs in the country.

The growing prevalence of chronic diseases, including respiratory diseases and disorders, is also boosting the Japan generic drugs market demand. According to an article published in Dove Medical Press in May 2024, the prevalence of airflow obstruction in Japan is 3.8%-16.9%. This bolsters the requirement for generics as they are equivalent to their brand-name counterparts in route of administration, strength, quality, and dosage while providing patients with an economical alternative. To reduce the national healthcare expenditure, the Japanese government has also implemented various policies to encourage the adoption of generics.

Additionally, the growing utilization of products by both healthcare professionals and patients can also be attributed to the increasing awareness about the benefits offered by them, which, in turn, is boosting the Japan generic drugs market size. Additionally, the Ministry of Health, Labor and Welfare (MHLW) proposed measures to promote generics for FY2022 reimbursement reform.

Furthermore, a study published in Biomed Central in February 2023 observed that the rate of generic prescription utilization for outpatient in-hospital prescriptions and out-of-hospital prescriptions increased as the monthly personal incomes of patients decreased.

The increasing prevalence of diseases such as cancer, diabetes, and cardiovascular diseases is driving the demand for generic drugs. These chronic conditions often require long-term medication, and the use of generic drugs enables patients to manage their conditions in a cost-effective manner, thereby highlighting the vital role of generic drugs in managing chronic diseases.

Government Encouragement Provides Growth Opportunities

The Japanese government is increasingly investing in educational campaigns to bolster public awareness and boost the utilization of generic drugs. The country's health ministry is also encouraging bigger drug manufacturers to merge with the small ones to propel the production of generics and ensure a stable supply. The ministry also aims to revitalize the pharmaceutical industry to accelerate domestic drug development. Medications are one of the main expenses of the healthcare system; possible reduction in drug costs is an everlasting concern for the government and policymakers to reduce expenditures, extend medical coverage, and improve access to medications. Thus, augmenting the adoption of generic drugs and positively influencing the market's growth.

Expansion of the Aging Population Boosts Market Demand

Over the past few decades, a push toward generic drugs have been witnessed to reduce costs in the healthcare sector due to the growth of the aging population. As per the estimates of the World Economic Forum, almost a third of the Japanese population is older than 65, and more than 1 in 10 individuals in the country are 80 or older. This growth is augmenting the requirement for generic drugs in the country as the older population is more susceptible to various diseases and disorders and regularly needs medications. As the generic drugs carry the same active ingredient as their brand name counterparts, they have the same administration, efficacy, dosage, and effect as the patented drug while being economically efficient. Thus, the preference for generics is increasing in the country.

Branded Generics Account for Major Market Share

The rising prevalence of various chronic diseases and increasing product launches by market players are supporting the growth of the Japan generic drugs market. In April 2023, Mochida Pharmaceutical Co., Ltd. announced the launch of Treprost Inhalation Solution, indicated for pulmonary arterial hypertension. The product contains Treprostinil as the active ingredient. Pulmonary arterial hypertension is characterized by elevated pulmonary artery pressure caused by the hardening and narrowing of pulmonary arteries responsible for carrying blood from the heart to the lungs. Symptoms including dizziness, fatiguability, and palpations accompany the orphan refractory disease. The market players are actively investing in the launch of branded generics to manage and treat such chronic conditions in Japan.

Biosimilars Hold Significant Market Share

Various biosimilars are being launched in Japan to ensure the availability of economically efficient treatment options for patients combatting chronic diseases. In December 2023, Sandoz Group AG and Biocon Biologics Limited announced a partnership for promoting, distributing, and selling Adalimumab in Japan. Under the agreement, Sandoz holds exclusive rights for the distribution and sale of the subcutaneous injection of Adalimumab BS in Japan. Adalimumab, the biosimilar version of Humira, is indicated for rheumatoid arthritis. Such collaborations and partnerships are expected to support the segment's expansion and boost the Japan generic drugs market's growth. The adoption of biosimilars is rapidly increasing in the country due to the growing awareness about their efficacy and safety among the general population.

Future Market Scenario (FY2025-FY2032F)

As per the Japan generic drugs market analysis, the growth of the market is boosted by the ongoing efforts of the Japanese government to propel awareness about generics, the increasing prevalence of chronic diseases, and the rapid aging of the country's population. According to the Population Projections for Japan (2023) in the National Institute of Population and Social Security Research, the number of people of ages 75 and above will increase to 22.58 million in 2030. The increasing investments by pharma companies towards the expansion of their generic portfolios and the launch of new biosimilars in the country are further expected to provide lucrative growth opportunities to the market.

Key Players Landscape and Outlook

Increasing collaborations to ensure a consistent supply of generics in Japan is supporting the market's expansion. Due to the efficacy offered by generic drugs and the assurance of cost efficiency, they are becoming increasingly popular in Japan. In order to ensure their availability, Meiji Seika Pharma, Me Pharma Co., Ltd., and Medreich Limited announced collaboration in July 2023 to establish a sustainable business model for generics. Through this collaboration, the companies are determined to create a unique business model to ensure a steady supply of generic drugs at nominal prices while generating profits for their sustainability. The companies are dedicated towards refining their processes and building rigorous quality control systems to meet all the requirements of Japan.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Executive Summary

4. Japan Generic Drugs Market Outlook, FY2018-FY2032F

• 4.1. Market Size Analysis & Forecast
  • 4.1.1. By Value
  • 4.1.2. By Volume
• 4.2. Market Share Analysis & Forecast
  • 4.2.1. By Application
    • 4.2.1.1. Neurovascular
    • 4.2.1.2. Cardiovascular
    • 4.2.1.3. Dermatology
    • 4.2.1.4. Oncology
    • 4.2.1.5. Diabetology
    • 4.2.1.6. Respiratory
    • 4.2.1.7. Others
  • 4.2.2. By Type
    • 4.2.2.1. Biosimilar Generics
    • 4.2.2.2. Small Molecule Generics
  • 4.2.3. By Brand
    • 4.2.3.1. Branded Generic
    • 4.2.3.2. Pure Generic
  • 4.2.4. By Route of Administration
    • 4.2.4.1. Oral
    • 4.2.4.2. Injectable
    • 4.2.4.3. Topical
    • 4.2.4.4. Others
  • 4.2.5. By Distribution Channel
    • 4.2.5.1. Hospital Pharmacy
    • 4.2.5.2. Retail Pharmacy
    • 4.2.5.3. Online Pharmacy
  • 4.2.6. By Region
    • 4.2.6.1. North [Hokkaido and Tohoku]
    • 4.2.6.2. Central [Kanto and Chubu]
    • 4.2.6.3. South [Kansai, Chugoku, Shikoku, and Kyushu & Okinawa]
  • 4.2.7. By Company Market Share Analysis (Top 5 Companies and Others - By Value, FY2024)
• 4.3. Market Map Analysis, FY2024
  • 4.3.1. By Application
  • 4.3.2. By Type
  • 4.3.3. By Brand
  • 4.3.4. By Route of Administration
  • 4.3.5. By Distribution Channel
  • 4.3.6. By Region

5. Demand Supply Analysis

6. Import and Export Analysis

7. Value Chain Analysis

8. Porter's Five Forces Analysis

9. PESTLE Analysis

10. Pricing Analysis

11. Market Dynamics

• 11.1. Market Drivers
• 11.2. Market Challenges

12. Market Trends and Developments

13. Regulatory Framework and Innovation

• 13.1. Bioavailability/ Bioequivalence Studies
• 13.2. Regulatory Approvals

14. Patent Expiration

15. Case Studies

16. Competitive Landscape

• 16.1. Competition Matrix of Top 5 Market Leaders
• 16.2. SWOT Analysis for Top 5 Players
• 16.3. Key Players Landscape for Top 10 Market Players
  • 16.3.1. Takeda Pharmaceutical Co., Ltd.
    • 16.3.1.1. Company Details
    • 16.3.1.2. Key Management Personnel
    • 16.3.1.3. Products and Services
    • 16.3.1.4. Financials (As Reported)
    • 16.3.1.5. Key Market Focus and Geographical Presence
    • 16.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisition
  • 16.3.2. Teva Pharmaceuticals Industries Ltd.
  • 16.3.3. Sun Pharma Japan Limited
  • 16.3.4. Nichi-Iko Pharmaceutical Co., Ltd.
  • 16.3.5. OHARA Pharmaceutical Co., Ltd.
  • 16.3.6. DAIICHI SANKYO COMPANY, LIMITED
  • 16.3.7. Meiji Seika Pharma
  • 16.3.8. Biocon Biologics Limited
  • 16.3.9. Mochida Pharmaceutical Co., Ltd.
  • 16.3.10. NIHON GENERIC Co., Ltd.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

17. Strategic Recommendations

18. About Us and Disclaimer

List of Tables

• Table 1. Pricing Analysis of Products from Key Players
• Table 2. Competition Matrix of Top 5 Market Leaders
• Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
• Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

• Figure 1. Japan Generic Drugs Market, By Value, In USD Billion, FY2018-FY2032F
• Figure 2. Japan Generic Drugs Market, By Volume, In Number of Prescriptions, FY2018-FY2032F
• Figure 3. Japan Generic Drugs Market Share (%), By Application, FY2018-FY2032F
• Figure 4. Japan Generic Drugs Market Share (%), By Type, FY2018-FY2032F
• Figure 5. Japan Generic Drugs Market Share (%), By Brand, FY2018-FY2032F
• Figure 6. Japan Generic Drugs Market Share (%), By Route of Administration, FY2018-FY2032F
• Figure 7. Japan Generic Drugs Market Share (%), By Distribution Channel, FY2018-FY2032F
• Figure 8. Japan Generic Drugs Market Share (%), By Region, FY2018-FY2032F
• Figure 9. By Application Map-Market Size (USD Billion) & Growth Rate (%), FY2024
• Figure 10. By Type Map-Market Size (USD Billion) & Growth Rate (%), FY2024
• Figure 11. By Brand Map-Market Size (USD Billion) & Growth Rate (%), FY2024
• Figure 12. By Route of Administration Map-Market Size (USD Billion) & Growth Rate (%), FY2024
• Figure 13. By Distribution Channel Map-Market Size (USD Billion) & Growth Rate (%), FY2024
• Figure 14. By Region Map-Market Size (USD Billion) & Growth Rate (%), FY2024